CRISPR Gene Editing Market Based on Offering (Product, Software, Service), By Application (RNA Editing, In Vitro Genetic Depletion, Other Applications) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

CRISPR Gene Editing Market Introduction

CRISPR Gene Editing is a genetic engineering technique used in molecular biology to modify the genomes of living organisms. The CRISPR gene-editing approach is tremendously important in medicine and biotechnology because it allows for easy genome editing in vivo, with exceptionally high precision, and at a low cost. Agricultural products, food products, novel pharmaceuticals, and genetically modified organisms are all developed using this technology.

Pests and diseases can also be controlled using this method. An increase in the number of cases of somatic cell carcinoma around the globe has been a primary factor in the CRISPR gene editing market. Inherited genetic diseases are also treated by CRISPR gene editing. The advancement of genome engineering and genome editing, which has a wide range of applications in life sciences and healthcare, has shown to be extremely beneficial for future reasons.

The use of the CRISPR-Cas9 system for the diagnosis and assessment of prokaryote evolutionary analysis has increased as the field of genome editing has progressed. The genome-editing technique is mostly used to understand better how bacteria evolve. The invention of Cas9 technology, which focuses on somatic cell genome editing and seeks to speed up the treatment of various genetic illnesses, is the most significant advancement in CRISPR gene editing.

Detailed Segmentation

Based on Offering:

• Product
• Software
• Service

Based on Application:

• Disease Models
• Biomedicine
• CRISPR in the Treatment of Infection
• RNA Editing
• In Vitro Genetic Depletion
• Other Applications

Based on End User:

• Biotechnology and Pharmaceutical Companies
• Academic and Research Institutions

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics

Drivers for the Global CRISPR Gene Editing Market:

The increasing prevalence of cancer and other genetic abnormalities, the surging need for precision medications, and a large increase in healthcare R&D expenditures contribute to market expansion. Furthermore, this market is being fueled by an increase in private and public sector funding, the growth of the biotechnology and pharmaceutical industries, and significant advancements in sequencing and genome editing technologies.

Restraints on Global CRISPR Gene Editing Market:

Increasing concerns about the hazards and ethical challenges associated with gene editing could stifle the economic growth of this market. Furthermore, the high cost of genomic equipment is another stumbling block to the further expansion of the global gene editing market.

Opportunities for the Global CRISPR Gene Editing Market:

More efficient genome editing technologies are being sought by research organizations, pharmaceutical and biotechnology firms, and institutes to improve specificity and cost-effectiveness while simultaneously reducing turnaround time and human errors. Furthermore, the advancement of genome editing technologies has opened up a wide range of possibilities in domains like industrial biotechnology and agricultural research. These modern approaches are simple, highly efficient, cost-effective, and capable of multiplexing and high throughput. Growing geriatric populations and the increasing number of cancer cases and genetic abnormalities worldwide are also expected to drive up the demand for CRISPR gene editing.

Trends for the Global CRISPR Gene Editing Market:

Major players continue to contribute to this market through various growth strategies such as mergers & acquisitions, new product launches, approvals, partnerships and collaborations, government funding and investments, among others, to gain a competitive edge in the overall gene editing market.

Competitive Landscape

• Creative Biolabs
• CRISPR Therapeutics
• Editas Medicine
• Eurofins Genomics
• GenScript
• Horizon Discovery Ltd.
• Integrated DNA Technologies Inc.
• Intellia Therapeutics Inc.
• Beam Therapeutics
• Caribou Biosciences Inc.

Recent Developments of Major Players

In November 2018, GenScript Technologies Corp. produced a novel Cas9 enzyme with minimum needs.

In October 2017, DuPont Pioneer (the agricultural subsidiary of E.I. du Pont de Nemours and Company) announced a non-exclusive global licensing arrangement for CRISPR-Cas9 gene-editing technology in agriculture with the Broad Institute of MIT and Harvard. The Broad Institute is working on CRISPR-Cas technology and has many issued US patents in this field. DuPont Pioneer expects to have the next generation of waxy corn products on the market by 2019, thanks to the use of CRISPR-Cas-enabled enhanced breeding technologies.

For the CRISPR Gene Editing Market research study, the following years have been considered to estimate the market size: